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Introduction 
The prevalence of long-term conditions is increasing across the world due to improved 
treatments for acute conditions and an increase in life expectancy 1, 2. Importantly, people are 
now commonly living with multiple long-term conditions and this has important implications 
for the design and cost of health services 3. Those with higher numbers of long-term 
conditions have worse health-related outcomes and use health services more frequently 4, 5. 
The presence of multiple conditions adds complexity to disease management, for example 
disease-disease and disease-drug interactions are more likely to occur. Co-occurring 
conditions can be concordant i.e. similar in origin and treatment requirements or discordant 
i.e. apparently unrelated or requiring different treatments 1.  
The terms multimorbidity and comorbidity are used frequently in the medical literature, the 
first commonly defined as the presence of  two or more long-term conditions within an 
individual and the second as the presence of one or more long-term condition alongside an 
index condition 1, 2, 6. However, it is widely accepted that there is great variation in definitions 
and this makes comparison of populations difficult. A recent systematic review of systematic 
reviews examined definitions and methods of measurement of multimorbidity 7. The authors 
reported that multimorbidity is most commonly defined as the presence of two or more 
conditions within an individual, but there is variation in whether duration, severity, or 
clustering of conditions are considered. Various options for the measurement of 
multimorbidity, including weighted and unweighted options, were also examined and the 
authors concluded that the optimum measure depends on the purpose of the study. So, at the 
present time there remains no consensus on the optimal approach to measuring 
multimorbidity. Common measures include the Charlson Comorbidity Index (CCI)8,  
Elixhauser 9, and the Cumulative Illness Rating Scale (CIRS) 10. All are weighted measures, 
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but Elixhauser can also be used in an unweighted form. The CCI was designed to predict 
mortality and includes 16 conditions (including cerebrovascular disease and hemiplegia)8. 
Elixhauser is a more extensive measure, it includes 30 acute and chronic conditions and was 
developed to predict length of hospital stay, hospital charges and in-hospital death 9. The 
Cumulative Illness Rating Scale (CIRS) was developed to assess the medical burden of 
chronic illness, it includes 14 body systems categories 10 . By contrast, the Liu comorbidity 
index was specifically constructed, from a cohort in Japan, to be used in stroke outcomes 
research. It includes 41 conditions and is a weighted measure 11. When choosing a measure, a 
weighted one that has been validated for the outcome being considered and may be best , but 
where evidence is weak or multiple outcomes are being examined, then a simple count of 
conditions may be appropriate 7. Importantly, a clear reason for choosing a definition and 
measure should be provided, and it may even be appropriate to include acute conditions, 
biopsychosocial factors and risk factors in the measure if appropriate for the aim of the study 
7. It is currently unclear what data source is best suited to the measurement of multimorbidity, 
for example whether routinely collected or self-reported data are more helpful. Traditionally, 
routinely collected data has been considered to be more valid but this relies on accurate 
coding by clinicians and risks missing conditions such as depression or chronic pain that are 
often poorly coded. However, one risk with self-reported data is that it may omit conditions 
less ‘visible’ to patients such as chronic kidney disease.  
This paper focusses on multimorbidity in stroke.  Stroke survivors commonly have comorbid 
conditions 12, and these may arise due to a variety of biopsychosocial reasons.  Many 
concomitant conditions may be concordant, that is share risk factors and pathological disease 
processes with stroke for example heart disease, or may predispose an individual to stroke, 
for example atrial fibrillation (AF).  While other co-existing conditions may occur secondary 
to stroke, for example vascular dementia, or may be entirely unrelated or discordant, for 
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example breast cancer.  When measuring multimorbidity in stroke, how we define 
comorbidity will affect results, for example inclusion of conditions that are risk factors for 
stroke will make prevalence of comorbidity high.  The recent Academy of Medical Sciences 
document makes it clear that even if someone only has a cluster of concordant conditions 
then the person should still be considered multimorbid.   
There are several reasons why multimorbidity in stroke merits attention. The additive effect 
of illness burdens from multiple conditions may contribute to poorer health status, higher risk 
of mortality, poorer functioning and increased use of health services through several 
mechanisms ranging from increased treatment burden or workload of healthcare 13 to 
associated inflammatory processes which may be linked to increased levels of disability 14. 
The presence of multimorbidity may interfere with recommended treatments post-stroke, for 
example by inhibiting participation in rehabilitative therapies. Stroke can reduce a person’s 
capacity to manage health due to physical, cognitive and psychological sequelae, and this can 
be exaggerated by multimorbidity.  For example, a stroke survivor with comorbid peptic 
ulcer disease may be unable to tolerate anti-platelet medication, or the presence of comorbid 
rheumatoid arthritis may result in an individual struggling to participate in physiotherapy. 
Additionally, multimorbidity in stroke is associated with polypharmacy that may enhance the 
risk of drug-drug interactions, such as anti-platelets taken alongside non-steroidal anti-
inflammatory (NSAID) medication increasing bleeding risk.  
It is clear that we need to understand the prevalence of multimorbidity in stroke and its 
association with health-related outcomes, in order to better plan stroke health services. 
Unfortunately, this is not a straightforward goal, as the way in which we define and measure 
multimorbidity is likely to impact findings.  
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This paper aims to examine how multimorbidity has been defined in stroke how prevalence 
has been measured and how associated health-related outcomes have been studied. We will 
discuss the implications of our findings for clinical practice and highlight potential research 
gaps.  
 
Methods  
We searched Ovid Medline between Jan 1, 1946 and Feb 19, 2018 for published articles that 
examined the prevalence of multimorbidity in people with stroke and any associations with 
health-related outcomes. We used the terms ‘stroke’ OR ‘cerebrovasc*’ AND ‘comorbid*’, 
OR ‘multimorbid*’.  For this paper, we focussed on well-conducted, large studies and 
systematic reviews. 
 
Definition and prevalence of multimorbidity  
We found four large, well conducted studies that have provided information on the 
prevalence of multimorbidity in stroke 12, 15-17. These are summarised in Table 1. All  defined 
multimorbidity as two or more long term conditions but the conditions that were included 
varied greatly and only three provided an explanation for choice of conditions12, 15, 16. All four 
examined the prevalence of individual comorbidities, and three also looked at severity of 
multimorbidity, two by taking a simple count 12, 16and one by using the CCI 15. All used 
administrative data or health records as a data source, none used self-reported data. One study 
examined older stroke survivors over 66 years 16, and unsurprisingly prevalence of 
multimorbidity was higher in this study than in the others. Results, shown in Table 1, differed 
greatly between studies, most likely due to the variation in methods used. One study 
examined trends in comorbidity over an 18 year period (1994-2011) and found that the 
proportion of people with stroke who had any comorbidity increased from 40.5% to 47.0% 
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for ischaemic stroke and 32.0% to 44.7% for haemorrhagic stroke over that time15. The 
existing literature comes from high income nations and there is a lack of data reported from 
lower or middle-income countries. 
There has been limited exploration of prevalence of multimorbidity in stroke in relation to 
patient demographic and lifestyle factors. One community cohort study in the UK (n= 8751) 
found higher number of comorbidites in stroke survivors who were female, older, socio-
economically deprived, and smokers12.    
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Table 1. Large, well-conducted studies that have examined prevalence of multimorbidity in stroke. 
Study Country Sample Sample 
size 
Data source Definition of multimorbidity Measure of 
multimorbidity and 
result 
Prevalence of 5 most 
common comorbidities 
reported in the paper 
Schmidt 
et al15 
Denmark First-time 
stroke, ≥15 
yrs 
219,354 Inpatient and 
outpatient health 
records 
 ≥ 1 other LTC within 15 yrs 
prior to stroke, excluding 
codes during stroke 
admission. Conditions in CCI 
chosen plus atrial fibrillation 
or flutter 
Charlson 
Comorbidity Index: 
42.8% ≥1; 18.5% 
moderate; 13.2% 
severe; 11% very 
severe 
Atrial fibrillation or flutter 
11.0%, cancer 10.9%, 
diabetes 9.0%, congestive 
heart failure 8.1%, chronic 
pulmonary disease 8.1%,  
Gruneir 
et al16 
Canada Stroke at 
least 6 
months 
prior,    ≥66 
yrs 
29,673 Administrative 
data from health 
insurance records 
≥ 1 other LTC prescription 
that suggests comorbidity in 
5 yrs prior stroke, from 14 
highly prevalent / author 
preferences 
Count of 
conditions: 99.1% 
≥1; 51.7% ≥4; 6.5% 
≥7 
Hypertension 89.9%, 
arthritis 65.8%, IHD 38.1%, 
diabetes 35.6%, COPD 
30.1%,  
Gallacher 
et al12 
UK Diagnosis of 
stroke or 
TIA ≥18 
35,690 Primary care 
health records 
≥ 1 other LTC from 39 
selected for previous 
research, informed by 
systematic review. Unknown 
if predate or postdate stroke 
Count of 
conditions: 94.2 % 
≥1    44.5% ≥ 4    
10.1% ≥7  
Hypertension 60.9%, 
coronary heart disease 
29.5%, painful condition 
21.9%, depression 20.7%, 
diabetes 18.8%,  
Johansen 
et al17 
Canada First time 
stroke ≥20  
32,107 Hospital discharge 
records. 
≥ 1 other LTC from 14, 
unclear why they were 
selected or if they predate or 
postdate stroke 
None  Hypertension 35%, 
Diabetes 17%,arrhythmia 
15%, IHD 14%, other stroke 
12.8% 
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Associations with health-related outcomes 
Mortality 
There is evidence that multimorbidity is associated with higher risk of mortality in stroke 
patients. The relationship between multimorbidity and mortality among stroke patients has 
been studied for both shorter (in-hospital or within 30 days) and longer (>6 months) durations 
of follow-up and results are detailed in Table 2. Most studies have used CCI to measure 
multimorbidity, which was developed to predict inpatient mortality. In one landmark study 
involving more than 200,000 stroke patients from the Danish national registry, 
multimorbidity measured by CCI was consistently found to have a dose-response relationship 
with 30-day and 5-year mortality risk, over an 18-year period 15. Other work using this 
registry has shown that comorbidity, especially cancer and advanced renal or liver disease, 
increased one year mortality after stroke beyond the combined individual effects of stroke or 
the comorbidity 18. Two community studies (in the United States and Spain) found that 
multimorbidity measured by CCI was a significant predictor of six-month mortality in stroke 
patients 19, 20.  There is also evidence supporting a relationship between CCI score and risk of 
long-term mortality in stroke patients.   A 29% higher adjusted risk of one-year mortality 
with each unit increase in CCI, was reported in a study of 960 stroke patients21. A CCI score 
of ≥3 was found to have a higher 3-year and 9-year mortality risk, in a study of 959 stroke 
patients in Brazil22.   
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Table 2. Studies that have examined associations between multimorbidity and mortality.  
Study Country Study 
Type 
Sample 
size 
Data source Measure of 
multimorbidity 
Follow-up 
duration 
Key Results 
Schmidt et 
al15 
Denmark Cohort 219,354 Hospitalization 
records 
Charlson Comorbidity 
Index (CCI): 0(none), 
1(moderate), 2(severe), 
3(very severe)                           
30 days and 5 
years 
Stroke patients with very severe 
comorbidities had a 23.5% and 74.5% 
mortality risk at 30 days and 5 years 
respectively, compared to 10.5% and 
36.6% for stroke patients with no 
comorbidities at baseline. 
Jimenez et 
al19 
Spain Cohort  175 Hospitalization 
records 
CCI: 0-1 (low),2 or more 
(high)                                         
6 months Stroke patients with high CCI had 68.4% 
greater odds of mortality at 6 months.  
Berlowitz 
et al20 
US Cohort 2402 Hospitalization 
records 
3 different methods: CCI, 
Ambulatory Care Group 
(ACG, Diagnostic Cost 
Group (DCG) 
6 months Comorbidity was a significant predictor 
of all-cause mortality at 6 months for 
stroke patients, ACGs and DCGs 
performed better than CCI. The actual 
effect sizes were not reported.  
Goldstein 
et al21 
US Cohort 960 Hospitalization 
records 
CCI: 0-1 (low) 2 or more 
(high)                                         
1 year Stroke patients with high CCI at 72% 
greater odds of mortality at 1 year.  
Castro et al 
22 
Brazil Cohort 959 Hospitalization 
records 
CCI: 0(none), 
1(moderate), 2(severe), 
3(very severe)                                     
3 years, 6 
years, and 9 
years
Stroke patients with very severe CCI had 
a hazard ratio of 2.45, 2.87 and 3.18 at 
3, 6 and 9 years respectively for all-
cause mortality compared to those with 
CCI=0 
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Zhu et al23 Canada Cohort Two 
samples; 
Total 5452 
Hospitalization 
records 
Elixhauser Index In-hospital 
mortality 
(duration not 
specified) 
Elixhauser index was a significant 
predictor of in-hospital mortality. The 
actual effect sizes were not reported.   
Gallacher 
et al24 
UK Cohort 8751 Community 
recruitment 
Number of comorbid 
conditions categorized 
into: 0,1,2,3,4,                                       
5 or more                                       
7 years Stroke patients with 5 or more 
comorbidities had a hazard ratio of 2.38 
for all-cause mortality at 7 years, 
compared to stroke patients with no 
comorbidities. 
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Studies using measures other than the CCI, such as The Elixhauser Comorbidity Index have 
shown a similar relationship between multimorbidity and mortality. In a study of more than 
5000 stroke patients in Canada, multimorbidity measured by the Elixhauser Index was 
associated with a higher rate of in-hospital mortality over the four-year study period 23. A 
study involving 8751 UK Biobank participants with stroke measured multimorbidity using a 
simple count of morbidities (n=42) and found nearly 1.5 times higher risk of mortality in 
those with two additional comorbidities and an approximately 2.5 times higher risk of 
mortality in those  with  ≥5  comorbidities over seven years (Figure 1)24.  
We found four studies that have investigated the influence of number versus type of 
comorbidities on mortality risk among stroke patients.  The Canadian study described above 
examined the effect of 30 comorbidities in the Elixhauser index on the risk of in-hospital 
mortality among 5,452 stroke patients. They reported a significant higher risk of death with 
the presence of congestive heart failure, but the effect of other comorbidities was unclear23. 
The Danish study described earlier compared the effect sizes of 16 comorbidities included in 
the CCI on mortality risk at 30 days and 5 years 15. They found a 15% higher mortality risk 
for presence of diabetes with end-organ damage, 20% for peripheral vascular disease, 25% 
for chronic pulmonary disease, 35% for congestive heart failure and  AF or atrial flutter, 45% 
for moderate to severe renal disease, and 1.8- to 2.4-fold for mild to severe liver disease, 
while presence of myocardial infarction and diabetes without end-organ damage was not 
found to have any significant association.  A meta-analysis of 13 studies involving N=59,598 
stroke patients 25 found  depression after stroke was associated with approximately 20% 
higher risk of mortality at 2-5 years. This has major implications for the management of 
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mental health in the stroke population, a largely neglected aspect of stroke recovery 13.  A UK 
Biobank study with a seven-year follow-up period, explored whether concordant or 
discordant comorbidity was associated with worse mortality.  This study found that the 
presence of any cardiometabolic comorbidity had similar effect size on the risk of all-cause 
mortality as did the presence of any non-cardiometabolic comorbidity, compared with no 
comorbidities in stroke.  
Functional outcomes 
Given the increasing demand for and limited capacity of rehabilitation services, there is 
growing interest in factors which may predict functional outcome following stroke and allow 
more effective targeting of resources 26. Presence of specific comorbidities can affect 
functional outcomes following stroke. For example, a meta-analysis of 12 longitudinal 
cohorts following stroke thrombolysis, comprising 14,801 patients, found that AF was 
associated with a reduced likelihood of favourable outcome (modified Rankin Scale ≤2) 27. 
By the same measure, diabetes mellitus was also associated with poorer functional outcomes 
following thrombolysis in a meta-analyses of 19 observational or intervention studies 28. 
Studies quantifying the relationship between multimorbidity and functional outcomes have 
reported contradictory findings 19, 20, 26, 29-32. There is variability both in the choice of scale 
used to quantify multimorbidity, and in the assessment of functional outcome. A recent 
systematic review and meta-analysis synthesised the findings of 15 studies assessing the 
impact of multimorbidity on functional outcome following inpatient stroke rehabilitation 26. 
The CCI was the most commonly used measure, with four out of eight studies showing 
significant associations between a higher CCI and poorer functional outcome. The Liu index 
was consistently associated with poorer functional status at discharge in three small studies 
(n=85, 106, and 175, respectively), as was the Comorbidity Severity Index in one study 
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(n=85), a weighted measure comprising 10 organ systems in which diseases are scored 
according to effects on functional limitation. The authors meta-analysed seven studies that 
used the Functional Independence Measure (FIM) to assess discharge functional outcome and 
included a range of comorbidity indices. These studies were highly heterogeneous, varied in 
their adjustment for baseline functional status or stroke severity, and had small sample sizes 
(range 85 to 260). Where more than one comorbidity index was assessed in a single study, the 
most strongly associated was included in the primary meta-analysis (CCI was excluded in 
favour of the Liu index), which showed a modest but statistically significant association 
between multimorbidity and poorer discharge FIM. In a sensitivity analysis including the CCI 
estimate, the results were no longer statistically significant. However, this analysis excluded 
the two largest studies to assess the impact of CCI on functional outcome 20, 32, as these did 
not report FIM at discharge. These two studies are shown in Table 3. One is a large French 
study of routine data 28,201 patient undergoing inpatient rehabilitation found CCI to be 
associated with less functional gain, adjusting for baseline functional dependence and length 
of stay 32. The other is a study of 2,402 patients undergoing inpatient rehabilitation in the 
USA that reported the CCI did not improve the overall fit (over age and sex) of models 
predicting change in FIM 20.  
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Table 3. Large studies in the systematic review by Kabboord et al examining associations between multimorbidity and functional 
outcomes excluded from the meta-analysis 
Study Country Sample Sample 
size 
Data 
source 
Measure of 
comorbidity 
Functional outcome 
measure 
Method of 
assessment 
Findings  
Schnitzler 
et al32 
France Any stroke, 
admitted for 
inpatient 
rehabilitation 
28,201 National 
hospital 
discharge 
database 
CCI Physical Dependence 
Score 
 
Change in 
physical 
dependence 
from 
admission to 
discharge 
from 
rehabilitation 
CCI associated with 
less functional gain 
(adjusted for age, 
sex, rehabilitation 
setting, stroke type, 
length of stay, 
admission physical 
dependence score) 
Berlowitz 
et al20 
USA Inpatient stroke 
rehabilitation. 
2,402 Routine 
clinical 
and 
adminis-
trative 
data 
CCI 
Adjusted 
clinical groups 
(ACG) 
Diagnosis cost 
groups (DCG) 
FIM – change during 
rehabilitation period. 
Model fit 
including 
age/sex 
compared to 
models 
including age, 
sex and each 
comorbidity 
score.  
No improvement in 
model fit with CCI or 
ACG over age/sex 
alone.  
Adding DCG to 
age/sex improved 
overall model fit for 
functional gain. 
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Few studies have assessed the impact of multimorbidity on outcomes at specific time points, 
with most assessing status at discharge from inpatient rehabilitation. Two small studies have 
assessed the impact of CCI on modified Rankin Scale at 1 month and 6 months, respectively. 
These were not included in the systematic review discussed above and are summarised in 
Table 4. One specifically recruited older patients (mean age 83, n=297) and found no 
association between CCI and poor outcome after adjusting for stroke severity and premorbid 
disability 29. By contrast the other found no association between CCI and poor outcome at 6 
months after adjustment for stroke severity 19. 
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Table 4. Studies assessing associations between multimorbidity and functional outcome at specific time-points rather than discharge 
from inpatient rehabilitation  
 
Caballero 
et al19 
Spain Ischaemic 
stroke or 
intracerebral 
haemorrhage 
175 Assessme
nt 6 
months 
following 
stroke 
CCI Modified Rankin scale 
(mRS) 
Poor outcome 
(mRS ≥2) at 6 
months 
CCI associated with 
mRS ≥2after 
adjustment for age, 
sex, vascular risk 
factors, and stroke 
severity) 
Denti et al29 Italy First ischaemic 
stroke 
297 Retrospec
tive 
hospital 
records 
CCI mRS Poor outcome 
(mRS ≥2) at 1 
months 
CCI not significantly 
associated with mRS 
≥2 at 1 month after 
adjusting for stroke 
severity and 
premorbid disability. 
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Utilisation and organisation of services 
We found little evidence on the associations between multimorbidity in stroke and healthcare 
utilisation. A Canadian study of older individuals with stroke (N = 29,673) showed that 
healthcare utilization increased (primary and secondary care, emergency department, home 
care visits and hospitalisations) with increasing number of comorbidities during the five years 
post stroke 16.  The majority of healthcare utilisation was for conditions other than stroke at 
all levels of multimorbidity and was three times higher in those with 8 comorbid conditions 
compared with those with none. The biggest increases in utilization were for acute care 
hospitalizations and emergency department visits. Unsurprisingly, associated healthcare costs 
also increased for those with increasing multimorbidity, and this was mainly explained by an 
increased use of acute care services 16.   
A small Canadian cohort study using clinical and administrative data collected in one hospital 
over a decade (N=987), showed that having at least one other comorbidity was related to a 
longer (>7 days) hospital stay for those with a haemorrhagic stroke. This resulted in costlier 
care, through both diagnostic and rehabilitation stages of care 33. There were 13 conditions in 
addition to stroke examined and no explanation was given from the authors as to why they 
were chosen. Hypertension was the most prevalent comorbidity and independent of all other 
long-term conditions studied, it was most strongly associated with having a longer stay, and 
alongside cerebrovascular disease, was linked to the highest overall cost of stay 33 
In a study of approximately 2,200 stroke survivors in Germany, previous stroke, diabetes, 
symptoms of internal carotid artery stenosis , or a count of >3 comorbidities, were all 
associated with insurance applications for long-term nursing care within  3.6 years of their 
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stroke 34. There were 9 conditions chosen for examination and again no reason was given for 
their selection.  
Discussion 
Summary of findings 
Multimorbidity in stroke is a growing healthcare challenge with estimates of prevalence 
ranging from 43% - 94% depending on the definition and measurement used. Prevalence has 
been estimated to be as high as 99% in those over 66 years.  
Multimorbidity in stroke has been reported to be associated with increased short and long-
term mortality, however the majority of studies have had a small sample size. The CCI is the 
most commonly used measure of multimorbidity in studies that examine associations with 
mortality.  It is unclear whether type of comorbidity, for example whether conditions are 
discordant or concordant, has an influence on mortality. There is some limited evidence to 
suggest that multimorbidity in stroke survivors is associated with greater stroke severity, 
lower baseline functional status, longer rehabilitation time, poorer functional gain, lower 
overall functional status following rehabilitation, longer hospital stays, increased readmission 
rates, higher overall health care utilisation in the longer term which is associated with 
increased economic costs. Measures that include assessment of severity of comorbidities 
appear to be more predictive of functional gain; however, the limited literature to date 
suggests baseline functional status is consistently the strongest predictor of outcome. 
Implications of multimorbidity for clinical practice 
The high prevalence of multimorbidity in stroke has important implications for the design of 
stroke health services.  Individuals with multimorbidity are more likely to experience 
complexity in their healthcare, enhancing risk of non-adherence and disengagement from 
health services.  This may contribute to the poorer outcomes and increased costs reported in 
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those with multimorbidity and stroke. Stroke rehabilitation trials often exclude those with 
comorbidity resulting in a lack of evidence about how best to manage these individuals 35.  
Current stroke guidelines do not take account of multimorbidity, leaving uncertainty about 
how best to achieve optimal outcomes in these individuals 36. Currently, most health systems 
operate a disease-focussed arrangement that is suboptimal for those with multimorbidity due 
to poorly co-ordinated care and service fragmentation 13. Multimorbidity can lead to a 
considerable workload of healthcare for stroke survivors, defined as treatment burden, which 
can negatively impact wellbeing 37.  Treatment burden includes the work of making sense of 
treatments, engaging with others to access services and treatments, attending appointments 
and investigations, taking medications, enduring treatment side effects, enacting lifestyle 
changes and self-monitoring activities. For example, individuals with stroke and 
multimorbidity are expected to attend separate appointments for each condition, often with 
little communication between clinicians. One potential consequence of multimorbidity is the 
prescribing of multiple medications (polypharmacy).  Polypharmacy is common in stroke, 
posing potential risks 12, especially with regard to the likelihood of adverse drug reactions 
(ADRs). There is qualitative evidence that polypharmacy in stroke increases perceived 
treatment burden, and can be a barrier to adherence 38 but little quantitative evidence about 
the potential risks of different patterns of polypharmacy. 
There is a need for a paradigm shift in our approach to the management of stroke in the 
context of multimorbidity with a move to prioritise individual patient goals and increased 
emphasis on understanding each individuals’ capacity to self-manage if we are to improve 
outcomes and reduce resource waste 37, 39.  An individual’s capacity to self-manage, 
particularly in the context of multimorbidity, will vary depending on personal factors, 
physical and cognitive abilities, social, financial, environmental and wider life circumstances 
37.  Delivering more person-centred services that are more likely to meet the needs of those 
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with stroke and multimorbidity will require greater use of multidisciplinary teams and more 
emphasis on integrated care approaches across the primary and secondary care interface that 
can provide better support and respond more appropriately to the needs of these complex 
individuals.  There is a need to shift focus to consider how we can better tailor services to 
provide the holistic, person-centred care that will be necessary to improve the experiences 
and outcomes of our increasingly multimorbid stroke populations.  It will also be important to 
include multimorbidity as a key factor when trying to risk stratify those with stroke in 
hospitals and in the community and when considering the best design and approaches that 
should be adopted within rehabilitation services.  
Evidence gaps and implications for research 
The first uncertainty that needs addressed by researchers is how to define and measure 
comorbidity and multimorbidity in a stroke population. Whether to include risk factors or 
sequelae of stroke is one important issue, as is whether to use a weighted or unweighted 
measure. The answers to these questions are likely to vary depending on the purpose of 
multimorbidity measurement. The wider multimorbidity literature and multimorbidity 
guidelines described earlier, define multimorbidity as the presence of two or more long term 
conditions, thus including hypertension or other conditions such as AF which are risk factors 
for stroke.  The published literature to date shows that multimorbidity in stroke has been 
consistently associated with higher risk of short and longer-term mortality. The published 
studies included conditions such as hypertension and AF in the morbidity count and both 
discordant and concordant conditions. Stroke patients with multimorbidity are a heterogenous 
population and it will be essential to gain a better understanding of modifiable risk factors for 
multimorbidity and patterns of multimorbidity, for example common clusters of conditions 
and associations with adverse health outcomes to enable better risk stratification. There is 
insufficient knowledge about these issues to permit clear recommendations to be made. 
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International bench marking studies would aid understanding and inform future intervention 
development and clinical guidelines in this area.  However, there will be a need to develop a 
consensus regarding the optimal approaches to measuring multimorbidity in those with stroke 
to enable cross country comparisons and more large-scale studies are required, particularly 
those that aim to understand the role of number versus type of comorbidities on the 
relationship between stroke, multimorbidity and mortality.   
There is a paucity of evidence on the relationship between multimorbidity and functional 
outcomes, in particular studies examining longer term functional outcomes. Similarly, large, 
high quality studies are required to better understand the associations between multimorbidity 
in stroke and healthcare utilisation. The mechanisms underpinning any increased service 
utilisation should also be explored, for example whether it is due to associated morbidities, 
polypharmacy or other factors such as frailty that are common in multimorbid populations. 
Although there is an emerging literature that frailty is associated with multimorbidity 40, even 
in younger age groups 41, and is important in multimorbid individuals 6, little is known about 
this in the context of stroke. We found no studies that investigated the impact of 
multimorbidity on quality of life post-stroke. This should be explored quantitatively and 
qualitatively in order to inform the future design of stroke services. Development of ways of 
measuring treatment burden and individual capacity to self-manage those with 
multimorbidity would aid identification of those are at risk of non-adherence either because 
of perceptions of being overburdened or limitations in their ability to cope with their burden 
of illness and the accompanying self-management demands. Polypharmacy is common in 
multimorbid stroke survivors but we know insufficient about the implications of this and in 
particular the risks, if any, posed by different patterns of polypharmacy in multimorbid stroke 
populations. There is also a lack of evidence to inform clinicians about the impact of 
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interventions for polypharmacy, such as deprescribing medications, on health-related 
outcomes.  
There is uncertainty about how best to manage those with stroke who are multimorbid due to 
a lack of randomised clinical trials (RCTs) that look specifically at or even explicitly include 
this patient group. As a result, it is unclear how to best risk stratify or organise services for 
stroke survivors with multiple conditions. Inclusion of these individuals in RCTs is vital to 
increase the evidence base for the vast majority of people with stroke.  Equally, we know 
insufficient about the biological mechanisms underpinning multimorbidity in those with 
stroke.  A greater understanding of these issues is important if we are to discover whether 
there might be any novel therapeutic targets that could be beneficial. Lastly, there is a paucity 
of evidence about the issues of multimorbidity in stroke from low and middle-income 
countries, and this should be addressed. Table 5 highlights key research priorities. 
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Table 5.  Research Priorities 
To develop a consensus on a standardised approach to the definition and measurement of 
multimorbidity in those with stroke. 
To examine associations between multimorbidity and health-related outcomes (mortality, 
functional outcomes, health-care utilisation, quality of life) through high quality, large-
scale cohort studies.  
To examine the influence of patient factors (for example, lifestyle or frailty) or type 
/clustering of conditions on outcomes in those with multimorbidity and stroke. 
To develop measures to better understand the treatment burden experienced by those with 
stroke and multimorbidity in order to identify targets for intervention. 
To examine the risks associated with different patterns of polypharmacy in those with 
multimorbidity and stroke. 
To undertake work with patients, carers and professionals to explore how stroke care 
services should be designed to better address the needs of people with stroke and 
multimorbidity. 
To include people with multimorbidity in pharmacological and non-pharmacological trials 
involving people with stroke and to ensure study populations are well described. 
 
Conclusion 
Current knowledge of multimorbidity in stroke is limited.  The existing evidence gaps need 
addressed if we are to improve health care delivery and outcomes for the many people with 
stroke who experience some degree of multimorbidity. Clinical guidelines for those with 
stroke need to acknowledge the importance of multimorbidity if we are to start to adapt 
services to better meet the needs of our increasingly complex patients. 
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Figure legend - Kaplan–Meier graph of death proportion versus comorbidities (n=8,751). 
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